The authors examined the effect and concentration dependency of bromocriptine on the inhibition of axial length elongation in the experimentally induced myopic chicken. Two day-old white Leghorn chicken was monocularly deprived of form vision by lid suture. We measured the axial length of chicken's eye by ultrasonography at 2 day, 2 week, 4 week, and 6 week following repeated ophthalmic dosing beginning at 2 day. The first group was instilled with 0.1 cc of Tris buffer solution, whereas the second, third, and fourth groups were instilled with 0.1cc of 0.01 %, 0.02%, 0.04% bromocriptine solution respectively. All solutions were instilled twice daily for 6 weeks. In the inhibition of axial length elongation, the third group (0.02% bromocriptine) was most effective at 2 week (p<0.05), whereas the second group (0.01% bromocriptine) was most effective at 4 and 6 week (p<0.05). In summary, the axial length elongation of eyeball was effectively retarded by bromocriptine with the best efficacy at 0.02% in short-term dosing while at 0.01% in long-term dosing.
Bromocriptine* ; Chickens* ; Sutures ; Tromethamine ; Ultrasonography

No abstract available.
Bromocriptine* ; Dopamine Agonists* ; Dopamine* ; Fertility* ; Hyperprolactinemia* ; Lisuride*

Bromocriptine(15-100 mg/day) alone and with L-dopa were studied for 10-30 months on 22 patients with Parkinson's disease. Patients who had never received L-dopa treatment either because it was never attempted or of intolerance from the onset was placed under Bromocriptine. The responses of patients were excellent. Its antiparkinsonism activity in comparable with that of L-dopa with the advantage of reducing the unwanted side effects of L-dopa during the reduction of its dosage, for patients who have been taking the drug. However, this decrease of dosage should be effected gradually, while the dose of Bromocriptine in being increased. Bromocriptine did not treat the "on-off" effects of L-dopa but reduced the cardiac complications, painful contractions and dyskinesia.
Bromocriptine* ; Dyskinesias ; Humans ; Levodopa ; Parkinson Disease*

seconds ; defects ; Visual Fields ; Prolactinoma ; Bromocriptine

The authors report one case of akinetic mutism with obstructive hydrocephalus. The patient suffered from multiple shunt failures and shunt revision. After multiple shunt revision, the patient fell into an akinetic-mute state. She appeared awake but was no response to painful somatosensory, loud auditory or threatening visual stimuli and she required total nursing care. This behavioral syndrome was no response to shunt revision but we were able to successfully treat a case of akinetic mutism after combination theraphy of Bromocryptine and Ephedrine.
Akinetic Mutism* ; Bromocriptine* ; Ephedrine* ; Humans ; Hydrocephalus ; Nursing Care

OBJECTIVE: To report the efficacy of vaginally administered bromocriptine. MATERIAL AND METHOD: Case report. RESULTS: The prolactin level was significantly decreased after the administration of bromocriptine vaginally. CONCLUSIONS: The vaginal administration of bromocriptine can be an alternative to oral administration in patients with hyperprolactinemia who show severe side effects.
Administration, Intravaginal ; Administration, Oral ; Bromocriptine* ; Humans ; Hyperprolactinemia* ; Prolactin

Akinetic mutism is a syndrome caused by various etiologies, and characterized by silent immobility and preserved alertness. The repetitive ventriculoperitoneal shunt for the recurrent hydrocephalus can be a forerunner of that. We present a man with akinetic mutism following two times of ventriculoperitoneal shunt revision. Akinetic mutism of the patient may be caused by the damage on the ascending dopaminergic projections. Symptoms were not alleviated by the normalization of ventricular size but by a large dose of bromocriptine.
Akinetic Mutism* ; Bromocriptine ; Cerebral Ventricles* ; Humans ; Hydrocephalus ; Ventriculoperitoneal Shunt

Neuroleptic malignant syndrome (NMS) is a fatal complication most often caused by an adverse reaction to neuroleptic or antipsychotic drugs, and is mostly brought out in the initial stage of medication. Late onset NMS after long term intake of neuroleptics is uncommon, and the neurochemical mechanism is undiscovered. We report a patient of late onset NMS after a long term intake of haloperidol who was successfully treated with dantrolene and bromocriptine.
Antipsychotic Agents ; Bromocriptine ; Dantrolene ; Haloperidol ; Humans ; Neuroleptic Malignant Syndrome

BACKGROUND: Ropinirole is a non-ergoline D2 agonist which has a highly selective affinity to D2 receptor. The aim of this study was to evaluate the efficacy and safety of ropinirole in the treatment of Parkinson's disease (PD). METHODS: Seventy-six cases with PD (Hoehn and Yahr stage II to IV) were included in this trial. Each patient was randomly allocated to receive either ropinirole (n=37) or bromocriptine (n=39) over a 16-week period. All subjects were not optimally controlled on levodopa due to motor fluctuations. The response rate was defined as the percentage of patients who had at least 20% reduction of levodopa doses. The clinical status was also assessed using the Unified Parkinson's Disease Rating Scale (UPDRS), Clinical Global Impression (CGI), and reduction of off durations. RESULTS: The end-point analysis, on an intention-to-treat basis, revealed significantly higher response rate in the ropinirole group compared with the bromocriptine group (odds ratio 2.995, 95% C.I. (1.157, 7.751)). A statistically significant improvement in CGI was also observed in the ropinirole group (p=0.046). The mean off duration was significantly reduced in the ropinirole group (p=0.0001). Other parameters using the UPDRS motor score or off duration did not show significant differences between the two groups. The overall incidence of adverse effects was not significantly different between the two groups. The most common side effects were dizziness, dyskinesia, and nausea/vomiting. No subjects were withdrawn from the study due to side effects. CONCLUSION: Ropinirole is a safe and well-tolerated drug and provides superior overall efficacy compared with bromocriptine as an adjunct to levodopa. (J Korean Neurol Assoc 19(2):102~109, 2001)
Bromocriptine ; Dizziness ; Dyskinesias ; Humans ; Incidence ; Levodopa* ; Parkinson Disease*

BACKGROUND: Ropinirole is a non-ergoline D2 agonist which has a highly selective affinity to D2 receptor. The aim of this study was to evaluate the efficacy and safety of ropinirole in the treatment of Parkinson's disease (PD). METHODS: Seventy-six cases with PD (Hoehn and Yahr stage II to IV) were included in this trial. Each patient was randomly allocated to receive either ropinirole (n=37) or bromocriptine (n=39) over a 16-week period. All subjects were not optimally controlled on levodopa due to motor fluctuations. The response rate was defined as the percentage of patients who had at least 20% reduction of levodopa doses. The clinical status was also assessed using the Unified Parkinson's Disease Rating Scale (UPDRS), Clinical Global Impression (CGI), and reduction of off durations. RESULTS: The end-point analysis, on an intention-to-treat basis, revealed significantly higher response rate in the ropinirole group compared with the bromocriptine group (odds ratio 2.995, 95% C.I. (1.157, 7.751)). A statistically significant improvement in CGI was also observed in the ropinirole group (p=0.046). The mean off duration was significantly reduced in the ropinirole group (p=0.0001). Other parameters using the UPDRS motor score or off duration did not show significant differences between the two groups. The overall incidence of adverse effects was not significantly different between the two groups. The most common side effects were dizziness, dyskinesia, and nausea/vomiting. No subjects were withdrawn from the study due to side effects. CONCLUSION: Ropinirole is a safe and well-tolerated drug and provides superior overall efficacy compared with bromocriptine as an adjunct to levodopa. (J Korean Neurol Assoc 19(2):102~109, 2001)
Bromocriptine ; Dizziness ; Dyskinesias ; Humans ; Incidence ; Levodopa* ; Parkinson Disease*